Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hpNK cell injection
- Development stage
- Unknown
- Lead developer
- Tumor Hospital Affiliated to Guizhou Medical University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
hpNK cell injection is an adoptive cell therapy consisting of high-purity human natural killer (NK) cells. Developed by The Affiliated Cancer Hospital of Guizhou Medical University, it is being evaluated in clinical trials for the treatment of CD20-positive relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The therapy is typically administered in combination with rituximab, a CD20-targeting monoclonal antibody, to leverage antibody-dependent cellular cytotoxicity (ADCC). By providing a concentrated population of NK cells, the treatment aims to enhance the immune system's ability to identify and destroy malignant B cells that have become resistant to standard chemotherapy regimens.
- Other names
- high-purity human natural killer cell injectionhpNK cells
02
Targets
FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on hpNK cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hpNK cell injection.